You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient’s perspective
|
|---|---|
| Published in |
Health and Quality of Life Outcomes, October 2013
|
| DOI | 10.1186/1477-7525-11-167 |
| Pubmed ID | |
| Authors |
Ishan Hirji, Shaloo Gupta, Amir Goren, Diana R Chirovsky, Alyson B Moadel, Eduardo Olavarria, Timothy W Victor, Catherine C Davis |
| Abstract |
The availability of the tyrosine-kinase inhibitor (TKI), imatinib, and later introduction of second generation TKIs, dasatinib and nilotinib, have not only improved clinical outcomes of patients with chronic myeloid leukemia (CML), but also provide multiple therapeutic options for CML patients. Despite the widespread use of these oral therapies, little is known about the impact of different treatment regimens on patient-reported outcomes (PROs) among CML patients. The objective of this study was to assess the impact of patient-reported treatment restrictions and negative medication experiences (NMEs) on satisfaction and other health outcomes among patients with CML treated with oral TKIs. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 2 | 67% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 88 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 2% |
| Brazil | 1 | 1% |
| Netherlands | 1 | 1% |
| Belgium | 1 | 1% |
| United Kingdom | 1 | 1% |
| Unknown | 82 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 13 | 15% |
| Researcher | 12 | 14% |
| Student > Ph. D. Student | 12 | 14% |
| Student > Bachelor | 8 | 9% |
| Other | 7 | 8% |
| Other | 13 | 15% |
| Unknown | 23 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 30% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 11% |
| Agricultural and Biological Sciences | 6 | 7% |
| Psychology | 5 | 6% |
| Biochemistry, Genetics and Molecular Biology | 4 | 5% |
| Other | 13 | 15% |
| Unknown | 24 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 October 2013.
All research outputs
#13,898,428
of 22,725,280 outputs
Outputs from Health and Quality of Life Outcomes
#1,078
of 2,155 outputs
Outputs of similar age
#115,046
of 209,506 outputs
Outputs of similar age from Health and Quality of Life Outcomes
#4
of 13 outputs
Altmetric has tracked 22,725,280 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,155 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one is in the 48th percentile – i.e., 48% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 209,506 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.